Is Low-Risk Hypertension Fact or Fiction?Cardiovascular Risk Profile in the TROPHY Study | Zendy

Stephen A. Nesbitt | Zendy; Stevo Julius | Zendy; D.R.P. Leonard | Zendy; Brent M. Egan | Zendy; Melissa Grozinski | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Is Low-Risk Hypertension Fact or Fiction?Cardiovascular Risk Profile in the TROPHY Study

Author(s) -

Stephen A. Nesbitt,

Stevo Julius,

D.R.P. Leonard,

Brent M. Egan,

Melissa Grozinski

Publication year - 2005

Publication title -

american journal of hypertension

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.009

H-Index - 136

eISSN - 1941-7225

pISSN - 0895-7061

DOI - 10.1016/j.amjhyper.2005.01.021

Subject(s) - medicine , trophy , blood pressure , candesartan , placebo , body mass index , overweight , risk factor , lipid profile , amlodipine , endocrinology , cardiology , cholesterol , angiotensin ii , pathology , alternative medicine , political science , law

The Trial of Preventing Hypertension (TROPHY) Study is designed to establish whether treating high normal blood pressure with a low-dose angiotensin receptor blocker, candesartan cilexetil, for 2 years reduces the rate of progression to hypertension compared with placebo treatment over a 4-year observation period. We are presenting the baseline cardiovascular risk factor profile of the 809 subjects randomized in the TROPHY Study. The risk factors in this analysis were as follows: cholesterol >or=200 mg/dl; LDL-cholesterol >or=160 mg/dL; HDL-cholesterol <or=40 mg/dL (for men), <or=50 mg/dL (for women); triglycerides >or=150 mg/dL; body mass index >or=25 kg/m2 (overweight and obese), fasting insulin >or=20 mU/mL; heart rate >or=80 beats/min; hematocrit >or=43.5 % (men) and >or=41.2% (women).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research